Literature DB >> 15221265

Gadolinium-based contrast media may be nephrotoxic even at approved doses.

Henrik S Thomsen1.   

Abstract

It is generally believed that gadolinium-based contrast media are not nephrotoxic at the approved doses for MR (<0.3 mmol/kg body weight). Recently, a patient with diabetic nephropathy required dialysis because of anuria 6-7 days after MR angiography with 0.14 mmol/kg body weight gadolinium-DTPA-BMA to assess renal artery stenosis. No special precautions (e.g., hydration) had been taken. The serum creatinine levels had been within 200 and 300 micromol/l for the last 3 years with a very slow increase. This case highlights that gadolinium-based contrast media can cause contrast medium-induced nephropathy even at doses below 0.2 mmol/kg body weight in patients with multiple risk factors.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15221265     DOI: 10.1007/s00330-004-2379-0

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  11 in total

1.  Gadolinium-DTPA as X-ray contrast medium in clinical studies.

Authors:  T Albrecht; P Dawson
Journal:  Br J Radiol       Date:  2000-08       Impact factor: 3.039

Review 2.  Diabetic nephropathy. Aspects of pathophysiology and treatment.

Authors:  Henrik Post Hansen
Journal:  Dan Med Bull       Date:  2003-11

3.  [Gadodiamide and gadolinium-DTPA as intravenous media in computed tomography].

Authors:  V Engelbrecht; J A Koch; M Rassek; U Mödder
Journal:  Rofo       Date:  1996-07

Review 4.  Are gadolinium-based contrast media really safer than iodinated media for digital subtraction angiography in patients with azotemia?

Authors:  Ulf Nyman; Barbara Elmståhl; Peter Leander; Mats Nilsson; Klaes Golman; Torsten Almén
Journal:  Radiology       Date:  2002-05       Impact factor: 11.105

Review 5.  Contrast-media-induced nephrotoxicity: a consensus report. Contrast Media Safety Committee, European Society of Urogenital Radiology (ESUR).

Authors:  S K Morcos; H S Thomsen; J A Webb
Journal:  Eur Radiol       Date:  1999       Impact factor: 5.315

6.  Nephrotoxicity of high-dose gadolinium compared with iodinated contrast.

Authors:  M R Prince; C Arnoldus; J K Frisoli
Journal:  J Magn Reson Imaging       Date:  1996 Jan-Feb       Impact factor: 4.813

7.  Safety of gadolinium contrast angiography in patients with chronic renal insufficiency.

Authors:  Albert D Sam; Mark D Morasch; Jeremy Collins; Gina Song; Richard Chen; F Scott Pereles
Journal:  J Vasc Surg       Date:  2003-08       Impact factor: 4.268

Review 8.  Actual clinical use of gadolinium-chelates for non-MRI applications.

Authors:  Holger M Strunk; H Schild
Journal:  Eur Radiol       Date:  2004-02-10       Impact factor: 5.315

9.  Gadolinium-containing contrast media for radiographic examinations: a position paper.

Authors:  Henrik S Thomsen; Torsten Almèn; Sameh K Morcos
Journal:  Eur Radiol       Date:  2002-08-16       Impact factor: 5.315

10.  Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomized trial. The Iohexol Cooperative Study.

Authors:  M R Rudnick; S Goldfarb; L Wexler; P A Ludbrook; M J Murphy; E F Halpern; J A Hill; M Winniford; M B Cohen; D B VanFossen
Journal:  Kidney Int       Date:  1995-01       Impact factor: 10.612

View more
  27 in total

Review 1.  Recent hot topics in contrast media.

Authors:  Henrik S Thomsen
Journal:  Eur Radiol       Date:  2010-12-07       Impact factor: 5.315

Review 2.  Emerging applications of nanotechnology for the diagnosis and management of vulnerable atherosclerotic plaques.

Authors:  Shann S Yu; Ryan A Ortega; Brendan W Reagan; John A McPherson; Hak-Joon Sung; Todd D Giorgio
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2011-08-10

3.  Morphological, contrast-enhanced and spin labeling perfusion imaging for monitoring of relapse after RF ablation of renal cell carcinomas.

Authors:  Andreas Boss; Petros Martirosian; Christina Schraml; Stephan Clasen; Michael Fenchel; Artistotelis Anastasiadis; Claus D Claussen; Philippe L Pereira; Fritz Schick
Journal:  Eur Radiol       Date:  2006-01-27       Impact factor: 5.315

Review 4.  Image-guided radiofrequency ablation of renal cell carcinoma.

Authors:  Andreas Boss; Stephan Clasen; Markus Kuczyk; Fritz Schick; Philippe L Pereira
Journal:  Eur Radiol       Date:  2006-10-05       Impact factor: 5.315

5.  A noncontrast-enhanced pulse sequence optimized to visualize human peripheral vessels.

Authors:  Kjell-Inge Gjesdal; Tryggve Storaas; Jonn-Terje Geitung
Journal:  Eur Radiol       Date:  2008-08-15       Impact factor: 5.315

6.  Gadolinium contrast media are more nephrotoxic than iodine media. The importance of osmolality in direct renal artery injections.

Authors:  Barbara Elmståhl; Ulf Nyman; Peter Leander; Chun-Ming Chai; Klaes Golman; Jonas Björk; Torsten Almén
Journal:  Eur Radiol       Date:  2006-08-05       Impact factor: 5.315

7.  Contrast-enhanced dynamic MR nephrography using the TurboFLASH navigator-gating technique in children.

Authors:  Andreas Boss; Juergen F Schaefer; Petros Martirosian; Hans-Walter Hacker; Kassa Darge; Claus D Claussen; Klaus Küper; Fritz Schick; Heinz-Peter Schlemmer
Journal:  Eur Radiol       Date:  2006-04-22       Impact factor: 5.315

Review 8.  Contrast induced nephropathy: updated ESUR Contrast Media Safety Committee guidelines.

Authors:  Fulvio Stacul; Aart J van der Molen; Peter Reimer; Judith A W Webb; Henrik S Thomsen; Sameh K Morcos; Torsten Almén; Peter Aspelin; Marie-France Bellin; Olivier Clement; Gertraud Heinz-Peer
Journal:  Eur Radiol       Date:  2011-08-25       Impact factor: 5.315

9.  Gadolinium-promoted cell cycle progression with enhanced S-phase entry via activation of both ERK and PI3K signaling pathways in NIH 3T3 cells.

Authors:  Li-Juan Fu; Jin-Xia Li; Xiao-Gai Yang; Kui Wang
Journal:  J Biol Inorg Chem       Date:  2008-10-25       Impact factor: 3.358

10.  One-molar gadolinium chelate (gadobutrol) as a contrast agent for CT angiography of the thoracic and abdominal aorta.

Authors:  José M Esteban; Antonio Alonso; Vicente Cervera; Vicente Martínez
Journal:  Eur Radiol       Date:  2007-02-07       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.